What is JNJ's current stock price?

As of now, JNJ is trading at $148.69, with a daily change of -1.51%.

What are JNJ stock strengths?

JNJ strengths include Pays a reliable dividend, Earnings are forecast to grow, Trading below its fair value, Upgraded on attractively valued, .

What are the risks associated with JNJ stock?

JNJ Key risk is its Low Risk Level, .

What is JNJ next earnings date?

JNJ next earnings report is scheduled for Apr 15, 2025.

What is JNJ's current stock rating?

JNJ's current stock rating is Buy.

Should I buy JNJ stock right now?

Based on the current rating of Buy, it is advisable to consider Buy as your next step with JNJ stock.

Is JNJ a Strong Buy right now?

JNJ's current stock rating is Buy, which indicates whether it is a Strong Buy, Buy, Hold, Sell, or Strong Sell.

What does a 'Strong Buy' rating mean for JNJ?

A 'Strong Buy' rating for JNJ indicates that analysts are highly confident in the stock's potential for future growth.

What does a 'Strong Sell' rating mean for JNJ?

A 'Strong Sell' rating for JNJ suggests that analysts anticipate the stock will decline significantly and may not be a good investment.

What factors influence JNJ's stock rating?

JNJ's stock rating is influenced by factors such as market trends, earnings reports, risk factors, and overall sentiment from analysts.

Johnson & Johnson (JNJ) Stock Analysis and Insights

LOGIN

Market Overview Trending Stocks Stock Screener Trade Ideas

Top Rated Most Active Strong Potential Positive Momentum Earnings Calendar

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist

JNJ

Johnson & Johnson

$148.69

-$2.28 | -1.51%

Overview

Analysis

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

Open

$ 150.37

MKT CAP

$ 358.32B

High

$ 151.20

VOL

$ 13.69M

Low

$ 145.13

AVG VOL

$ 10.65M

Chart

167.28

147.77

155.01

146.82

1year

6month

3month

1month

JNJ Latest Headlines +

Johnson & Johnson reports promising results from skin disease trial.

Thu Apr 10, 2025

Activity

Seeking Clues to Johnson & Johnson (JNJ) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics. Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025 looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Thu Apr 10, 2025

Earnings

Johnson & Johnson Protagonist Tout Positive Results For Psoriasis Oral Pill Study. ) on Thursday announced new data for a pill that treats moderate-to-severe plaque psoriasis. The Phase 3 study was conducted in .The ICONIC program with icotrokinra (JNJ-2113) data from a subgroup analysis came about through a partnership with ).Data at the 2025 World Congress of Pediatric Dermatology (WCPD) Annual Meeting show adolescents treated with once daily icotrokinra achieved higher rates of clear or almos

Thu Apr 10, 2025

Activity

Jim Cramers Take On Johnson & Johnson (JNJ): Are Litigation Fears Creating a Rare Buying Opportunity?.

Thu Apr 10, 2025

Momentum

This Johnson & Johnson Analyst Turns ish On Shifting Focus From Stelara Concerns To Innovative Medicine. While the consensus seems to underappreciate the trajectory of) upgraded the rating from Neutral to Buy while raising the price target from $157 to $172.

Wed Apr 9, 2025

Activity

Potential

Rating

Johnson & Johnsons New Compelling Data Shows Sustained Symptom Improvement In Muscular Disease Patients. ) on Tuesday announced results from additional analyses of the Phase 3 Vivacity-MG3 study and the ongoing open-label extension(OLE) evaluating the long-term efficacy and safety of nipocalimab in a broad population of antibody-positive adults with .Patients treated with nipocalimab plus standard of care (SOC) maintained improvements in their MG-ADL (activities of daily living)and QMG (quantifi

Tue Apr 8, 2025

Activity

Potential

J&J upgraded. Pfizer AbbVie downgraded as Goldman reviews United States biopharma coverage.

Tue Apr 8, 2025

Rating

Johnson & Johnsons Tremfya Shows Efficacy In Late-Stage Psoriatic Arthritis Study. ) on Friday announced topline results from Phase3bAPEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis (PsA) who are biologic naïve and have had an inadequate .The study achieved its primary endpoint (ACR20a) of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage as measured by radiographic progression at 24 weeks .In the Phase3bAPEX s

Fri Apr 4, 2025

Activity

Pharma Stock Roundup: FDA Nod to SNY AZN & NVS JNJ Talc Suits Failure. FDA approves SNYs hemophilia therapy fitusiran and NVS rare kidney disease drug Vanrafia.

Fri Apr 4, 2025

Activity

JNJ: TREMFYA Phase 3b Study Meets Key Endpoints In Adults With Active Psoriatic Arthritis . (RTTNews) - Drug major Johnson & Johnson (JNJ) announced Friday positive results from the TREMFYA (guselkumab) Phase 3b APEX study in adults living with active psoriatic arthritis or PsA compared to placebo.

Fri Apr 4, 2025

Activity

Explore our JNJ Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored JNJ Stock Strategies
Effective Risk Management

FIND US ON

Receive our JNJ Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

Ideas

Earnings

Overview

Analysis

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

JNJ

Johnson & Johnson

$148.69

-$2.28 | -1.51%

Chart

167.28

147.77

155.01

146.82

1year

6month

3month

1month

Discover JNJ Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of JNJ. We're here to help you make informed investment decisions today.

FIND US ON

Receive our JNJ Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

JNJ Stock trends

JNJ Stock performance

JNJ Stock analysis

JNJ investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

JNJ Stock Analysis for the Last 90 Days

JNJ Risk Level

JNJ Analysts Opinion

JNJ Street Consensus

JNJ Performance Sentiment

Technical Price Levels

JNJ Financial Health

Explore our JNJ Stock insights

Receive our JNJ Daily Alerts

JNJ Stock Analysis for the Last 90 Days

JNJ Street Consensus

Technical Price Levels

Discover JNJ Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of JNJ. We're here to help you make informed investment decisions today.

Receive our JNJ Daily Alerts